High cardiovascular event rates occur within the first weeks of starting hemodialysis
Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jürgen Floege(Westfälische Hochschule), Sharon Richards(Amgen (United Kingdom)), Marc Froissart(University of Lausanne), Stefan D. Anker(Bayer (Germany)), A L de Francisco(Universidad de Cantabria), Iain Gillespie(Amgen (United Kingdom)), Florian Kronenberg(Innsbruck Medical University), Daniele Marcelli(Fresenius Medical Care (Germany)), David C. Wheeler(University College London), Peter Stenvinkel(Karolinska Institutet)
Cited by 113
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k